In a recent segment of MidasLetter Live, Canntab Therapeutics (CSE:PILL) CEO Jeff Renwick and CFO Richard Goldstein spoke to Midas about the work the company has done in recent months to double the company’s valuation.

During the segment, Renwick and Goldstein provided an overview of what Canntab does, which is to transform cannabis resins into hard tablet/pill form. The company is developing these products as they await for Health Canada approval of hard tablets as a viable form of oral consumption of cannabis. To Canntab, the value of hard tablets is that they protect cannabinoids from degradation as they pass through the digestive system. They also offer a more stable delivery method.


In terms of revenue, Canntab is generating licensing fees from their deal with Emblem (TSXV:EMC,OTCQX:EMMBF), a fully integrated licensed producer and distributor of medical cannabis and cannabis derivatives in Canada. Under the licensing agreement, Emblem has agreed to develop and market three of Canntab’s products. Canntab also expects to conduct its first product sales in 2019.

The company is focused on developing both THC and CBD products. For the latter, Goldstein emphasized the importance of using full-spectrum CBD oils, which will now be available following legalization. Full-spectrum CBD can be extracted from the hemp plant. Up until now, hemp oil could only be extracted from the hemp seed, which does not have as much CBD value. Canntab plans to encapsulate full-spectrum CBD oil into tablets and market that product, serving the medical market particularly.

The Canntab executives emphasized that despite the potential innovations on the horizon for cultivating cannabinoids, whether it be through the cannabis plant or in the laboratory, there will always be a need for effective delivery methods, and that is what Canntab can provide.

To watch the full interview, click here.

Click here to connect with Canntab Therapeutics (CSE:PILL) for an Investor Presentation.

US-based multi-state operators (MSOs) performed well during Q1, but one fund manager believes that hasn’t been reflected in their share prices.

Keep reading... Show less

 Aion Therapeutic Inc. (CSE: AION) (” Aion Therapeutic ” or the ” Company “) announced today that its proprietary and patented combinatorial mushroom preparations AION F7 and AION F8 (collectively, the ” Aion Mushroom Preparations ” or ” Preparations “) showed high efficacy in killing HER2+ breast cancer cells, ER+PR+ breast cancer cells, and triple-negative breast cancer cells by direct cytotoxicity.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (FSE: L0MA) (“Nextleaf”, “OILS”, or the “Company”) , the world’s most innovative cannabis processor, is pleased to announce that its wholly-owned subsidiary Nextleaf Labs Ltd. (“Nextleaf Labs” or “Labs”) has completed an inaugural bulk CBD distillate delivery to a U.S.-listed, Canadian-based global cannabis company. The Company anticipates similar orders on an ongoing basis.

Keep reading... Show less

The Company Will Tap into Southern Glazer’s Established Distribution Network to Bring Quatreau, its CBD-Infused Sparkling Water, to U.S. Retailers

 Canopy Growth Corporation (“Canopy Growth”) (TSX: WEED) (NASDAQ: CGC), a world-leading diversified cannabis, CBD and vaporization device company, today announced Southern Glazer’s Wine & Spirits (“Southern Glazer’s”), the world’s pre-eminent distributor of beverage alcohol, as the distribution partner for its U.S. portfolio of CBD-infused beverages. This partnership announcement follows the recent launch of Quatreau Canopy’s first line of CBD-infused beverages sold in the U.S market.

Keep reading... Show less

 Canbud Distribution Corporation (CSE: CBDX) (FSE: CD0) (“Canbud” or the “Corporation”) announces its subsidiary Empathy Plant Co. has completed the full development of its vegan multivitamin formula exclusively for women.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7448/81051_95aa98db045cb95d_001.jpg
Unique Vegan Women’s Multi-Vitamin with 100% Compostable Packaging

Keep reading... Show less